Celldex Shares Drop After Phase 2 Trial Results Miss Targets
Celldex (CLDX) shares fell approximately 6% after hours following phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints in treating prurigo nodularis. The underperformance of the drug's efficacy metrics likely contributed to investor disappointment.
Tickers: $CLDX
Topics: biotech clinical trials prurigo nodularis